Related Experiment Video

Updated: Aug 21, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy

Joachim L Schultze1, Stephan Grabbe, Michael S von Bergwelt-Baildon

  • 1Molecular Tumor Biology and Tumor Immunology, Clinic I for Internal Medicine, University Hospital Cologne, University of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany.

Trends in Immunology
|November 9, 2004
PubMed

Insights

Cellular cancer immunotherapy, like dendritic cell vaccines, shows promise in generating tumor-specific T cells. However, clinical trials yield disappointing results, highlighting a gap between preclinical data and patient outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Tumor-host immune interactions are complex and not fully understood.
  • Cellular vaccines, particularly dendritic cells, can generate tumor antigen-specific T cells in preclinical models and humans.
  • Encouraging preclinical results have led to clinical trials for cancer immunotherapy.

Purpose of the Study:

  • To address the discrepancy between preclinical data and clinical outcomes in cellular cancer immunotherapy.
  • To propose new research directions for improving the efficacy of cellular cancer immunotherapy.

Main Methods:

  • Review of preclinical findings and clinical trial outcomes in cellular cancer immunotherapy.
  • Analysis of potential reasons for the gap between preclinical success and clinical disappointment.

Main Results:

  • Preclinical studies reliably generate tumor antigen-specific T cells using cellular vaccines.
  • Clinical trials for cellular cancer immunotherapy have yielded disappointing results to date.
  • A significant discrepancy exists between preclinical data and clinical response rates.

Conclusions:

  • The translation of cellular cancer immunotherapy from preclinical models to human trials may be sub-optimal.
  • Preclinical models might not accurately represent the human tumor-host immune environment.
  • New clinical research strategies are needed to enhance cellular cancer immunotherapy effectiveness.

More Related Videos

Generation of Human CD40-activated B cells13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...